Navigation Links
Adenosine Therapeutics Engages Needham & Company to Explore Strategic Options for Phase III Cardiac Stress Agent
Date:4/1/2013

CHARLOTTESVILLE, Va., April 1, 2013 /PRNewswire/ -- Adenosine Therapeutics, LLC, a drug discovery and development company founded in 1999, announced today that it has engaged Needham & Company to explore strategic options for Stedivaze®, a highly selective adenosine A2A agonist being developed as a pharmacological stress agent for use in Myocardial Perfusion Imaging.

"We are seeking regional or global collaborators to rapidly conclude our Phase 3 clinical trials, which are more than halfway complete, and to pursue the approval, distribution, and marketing of Stedivaze®," said Adenosine Therapeutics Co-Founder and CEO Robert Capon . "Clinical trial data to date suggests Stedivaze® has the potential to demonstrate equivalent efficacy, compared to the standard of care, plus best-in-class product attributes, with the potential to expand the market for Cardiac Stress Agents."

"Stedivaze® has a strong patent estate with a long life," continued Robert Capon , "The pharmacological stress agent market is established, large (presently over $700 million in the United States), and growing. We believe that, with its potential best-in-class product characteristics, strong patent estate, and a large and growing market, that Stedivaze® represents an exceptional opportunity for the right partner. We are pleased to be working with Needham and Company to find such partner for this late-stage Specialty Pharma opportunity."

Adenosine Therapeutics, LLC is a drug discovery and development company founded in 1999. Adenosine Therapeutics holds the exclusive, worldwide license to the investigational compound apadenoson, the active pharmaceutical ingredient of Stedivaze®. The company re-acquired the exclusive, worldwide license to Stedivaze® on December 31, 2012. Two Phase 3 clinical trials for Stedivaze® are 52% complete.  The company is headquartered in Charlottesville, Virginia.

Needham & Company, LLC, a wholly owned subsidiary of The Needham Group, Inc., is a privately held, full-service investment bank that has focused exclusively on growth companies since it was founded 28 years ago. It concentrates on private companies and on public companies that have market capitalizations of up to $5 billion, and provides its clients with the resources to achieve their financing and strategic objectives. The Firm has capital raising expertise in IPOs, follow-on public equity offerings, confidentially marketed equity offerings, and private placements and in Mergers & Acquisitions and Corporate & Venture Services (including share repurchases). In addition to investment banking, Needham's activities include institutional sales and trading and asset management. To serve its institutional clients, Needham & Company, LLC produces comprehensive equity research on more than 350 companies in clean technology and industrial growth, communications and enterprise infrastructure, consumer, healthcare, semiconductors and semiconductor equipment, and software. The firm is headquartered in New York City with offices in Boston, MA, Menlo Park, CA, and San Francisco, CA. Needham & Company, LLC is a member of FINRA, SIPC & SIFMA.

Contact: Robert Capon , Chief Executive Officer, (434) 466-7812


'/>"/>
SOURCE Adenosine Therapeutics, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... , May 15, 2017  Amy Baxter MD, chief ... leader in noninvasive pain relief, was awarded a 2017 ... magazine. Baxter was recognized at the MM&M Top 40 ... York City on May 10, 2017. The ... biopharma industry go "beyond the pill."  "Innovation ...
(Date:5/10/2017)... 2017 Hologic, Inc. (Nasdaq: HOLX ... fiscal second quarter ended April 1, 2017 .   ... 666.7% compared to the prior year period as the ... significant gain, while non-GAAP diluted EPS of $0.50 increased ... in constant currency terms.  Excluding the effects of blood ...
(Date:5/10/2017)... 10, 2017 CSSi, the global leader in ... research industry, is proud to announce the launch of ... website features both enriched content and a customized layout ... the company,s already well-established position as the top global ... "After many months of hard work, we are delighted ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... Somnoware, a ... portable sleep monitor with its Somnoware Sleep Device Interface (SDI). Somnoware SDI is ... device operations. With this platform, initializing devices and importing studies are just one-click ...
(Date:5/26/2017)... MD (PRWEB) , ... May 26, 2017 , ... After ... anti-stress Antzy Top gadget will continue to be available at a discounted crowdfunding price ... deal with stress wherever they are, I also wanted to bring a fidget toy ...
(Date:5/26/2017)... ... ... “When the Stars Lead Home”: a poignant story of loss, determination, and ... Douglas, an avid reader who lives in the Pacific Northwest with her husband, daughter, ... Adventure Camp. She couldn’t be more grateful. , Twelve-year old Tizzy could not believe ...
(Date:5/26/2017)... ... ... Water damage to the flooring of several classrooms at The Fort Lee ... a number of critical issues to address before students could return to classes. , ... or no disruption to class schedules. Second, the project had to comply with New ...
(Date:5/24/2017)... Diego, California (PRWEB) , ... May 24, 2017 ... ... care through innovative medical image management and interpretation, has received U.S. Food and ... , Nucleus.io is a web-based, scalable and secure cloud platform for medical ...
Breaking Medicine News(10 mins):